Mirati Therapeutics reports 3 months of 2022

Mirati Therapeutics' GAAP loss for 3 months of 2022 was $188.386 million, up 38.8% from $135.68 million in the previous year. Revenues were $709 thousand. The company did not earn revenues a year earlier.